SHAPHAR China (Mainland)

Shanghai Pharmaceutical Co., Ltd. (known as Shaphar) is a leading publicly listed pharmaceutical company (Stock Code: 600849) , with business covering manufacture, wholesale, retail, Imp. & Exp. And distributing logistics across healthcare. Shaphar is also the only one company who owns the membership of International Federation of Pharmaceutical Wholesalers (IFPW) in China, with total assets of 6 billion Yuan and over 3200 employees working for human's better life. Based on mutual cooperation, Shaphar does its best to satisfy clients' diverse demands through the company's own factories and domestic purchasing. There are 10 factories in Shaphar's manufacturing section. We believe that the quality of medicine is the foundation of the company, so we innovate and improve the quality of product as part of our business cycle.The medicine manufacturing process is strictly complied with China's GMP standard, and Shaphar still proactively promotes the cGMP quality assurance. Currently 3 pharmaceutical raw materials, 1 small volume injection and 1 solid preparation have successfully entered into Australian, European and American markets.In 1998, Shaphar established Shanghai-Sudan Pharmaceutical Company jointly with Central Medical Supplies Public Group of Sudan based in Khartoum. The factory covers an area of approx. 2000M2, mainly producing medicines such as antibiotics, anti-malaria and antipyretic analgesics. The branded anti-malaria drug, ASP, developed by the company independently was the first one that accomplished registration and production locally, and soon became the best-seller in the market. Taking the advantage of Shaphar's strong and powerful domestic supplier chain, Shaphar also applies domestic purchase to meet customers' needs.Now, SHAPHAR's business partners can be found in over 30 countries, and the products are various including pharmaceuticals, medical devices, healthcare products and veterinary products. Relying on high-quality service and both products, Shaphar believes expertise and mutural partnerships enhance development potentially for both customers and ourselves.